ArticleESMO real world data and digital oncology2025

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

K Morimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.